Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.

INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. “Lilly had another strong growth quarter in Q3, with ...

Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the ...

The company got approval to sell its tirzepatide injections—branded as Mounjaro—in a device called Kwikpen. Mounjaro is designed for long-term weight management and the treatment of type 2 ...

Investing.com -- Eli Lilly & Co. (NYSE: LLY) plans to start selling its popular weight-loss medication, Mounjaro, in Hong ...

Eli Lilly (NYSE:LLY) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales ...

The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — ...

Those looking to fill a prescription with a prefilled pen — or "KwikPen" — over their usual vials to contact their health care provider. Those struggling to get the alternate product covered by ...